HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Erratum (v105,p1495) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moorman, P. G. Articles by Schildkraut, J. M. Search for Related Content PubMed PubMed Citation Articles by Moorman, P. G. Articles by Schildkraut, J. M. Related Collections Gynecologic oncology Epidemiology/public health

Antidepressant Medication Use for and Risk of Ovarian Cancer

Patricia G. Moorman, PhD^*, Andrew Berchuck, MD, Brian Calingaert, MS^*, Susan Halabi, PhD and Joellen M. Schildkraut, PhD^*

From the *Cancer Prevention, Detection, and Control Research Program, Department of Community and Family Medicine, Duke University Medical Center; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center; and Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.

OBJECTIVE: It has been hypothesized that antidepressants may enhance cancer growth. Previous studies of antidepressant use and ovarian cancer have been inconsistent and have been limited in their ability to examine the association with selective serotonin reuptake inhibitors (SSRIs), which are currently the antidepressants most commonly prescribed. The objective of this paper was to evaluate whether women with ovarian cancer were more likely to report past use of antidepressants than control women.

METHODS: Antidepressant use was assessed in a population-based, case-control study of ovarian cancer (593 cases, 628 controls). Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) associated with antidepressant use overall and by subcategories of antidepressants.

RESULTS: Antidepressant use was reported by 18% of cases and 20% of controls. No increased risk was observed for ever use of any type of antidepressant (OR 0.9, 95% CI 0.7–1.2) or for SSRIs (OR 1.0, 95% CI 0.7–1.5). There also was no evidence of increased risk with longer duration of use. Our study had greater than 80% power to detect an OR as small as 1.5. Thus, even a modest increase in risk associated with antidepressant use can be excluded with these data.

CONCLUSION: Our study adds to the growing body of evidence suggesting that antidepressants do not have a significant effect on ovarian cancer risk. In particular, the data suggest that SSRIs, which are the most commonly used class of antidepressants, are not associated with an increased risk for ovarian cancer.

LEVEL OF EVIDENCE: II-2

This article has been cited by other articles:

				J. Stebbing, T. Powles, S. Mandalia, M. Nelson, B. Gazzard, and M. Bower Use of Antidepressants and Risk of Cancer in Individuals Infected With HIV J. Clin. Oncol., May 10, 2008; 26(14): 2305 - 2310. [Abstract] [Full Text] [PDF]